Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Animal or plant cell
Reexamination Certificate
2011-04-19
2011-04-19
Lankford, Leon B (Department: 1651)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Animal or plant cell
C424S094600, C435S366000
Reexamination Certificate
active
07927587
ABSTRACT:
The present invention relates to methods for providing lysosomal enzymes to a subject by administering stem cells, preferably Multipotent Adult Progenitor Cells (MAPCs). The invention further relates to methods for treating lysosomal storage disorders by administering stem cells.
REFERENCES:
patent: 5310646 (1994-05-01), Whitley
patent: 5486359 (1996-01-01), Caplan et al.
patent: 5827735 (1998-10-01), Young et al.
patent: 5906934 (1999-05-01), Grande et al.
patent: 6090625 (2000-07-01), Abuljadayel
patent: 6214369 (2001-04-01), Grande et al.
patent: 6653134 (2003-11-01), Prockop et al.
patent: 6777231 (2004-08-01), Katz et al.
patent: 7056738 (2006-06-01), Prockop et al.
patent: 2001/0046489 (2001-11-01), Habener et al.
patent: 2002/0164794 (2002-11-01), Wernet
patent: 2003/0003090 (2003-01-01), Prockop et al.
patent: 2003/0059414 (2003-03-01), Ho et al.
patent: 2003/0186439 (2003-10-01), Nakauchi et al.
patent: 2004/0033217 (2004-02-01), Vanguri et al.
patent: 2004/0235165 (2004-11-01), Prockop et al.
patent: WO 96/23870 (1996-08-01), None
patent: WO-9923205 (1999-05-01), None
patent: WO-0111011 (2001-02-01), None
patent: WO 01/21767 (2001-03-01), None
patent: WO-02063962 (2002-08-01), None
patent: WO-02064755 (2002-08-01), None
patent: WO-03087333 (2003-10-01), None
patent: WO-03101202 (2003-12-01), None
patent: WO-2004015077 (2004-02-01), None
patent: WO-2004050859 (2004-06-01), None
patent: WO-2005016250 (2005-02-01), None
patent: WO-2005021716 (2005-03-01), None
patent: WO-2005056026 (2005-06-01), None
Koc et al. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 2002;30:215-222.
Tolar, J. , et al., “Multipotent Adult Progenitor Cells (MAPCs) Reduce Glycosaminoglycan (GAG) Accumulation in a Murine Model of Hurler Syndrome (MPS 1H)”,45th Annual Meeting of the American Society of Hematology, Blood 102(11), ISSN: 0006-4971,(Nov. 16, 2003),839a.
Tolar, J. , et al., “The in Utero Transfer of Murine Multipotent Adult Progenitor Cells (MAPCs) Result in Brain and Liver Differentiation”,43rd Annual Meeting of the American Society of Hematology,Blood 98(11), ISSN: 0006-4971,(Nov. 16, 2001),475a.
Aldous et al., “Flawed stem cell data withdrawn” New Scientist; (Feb. 15, 2007).
Aldous et al., “Fresh questions on stem cell findings” New Scientist; (Mar. 24, 2007).
Check “Stem cell paper corrected” Nature; 447:763 (2007) and Jiang et al., “Pluripotency of mesenchymal stem cells derived from adult bone marrow” Erratum in Nature; 447:879-880 (2007).
Chi, “Adult stem cell figure retracted” The Scientist; (Jun. 13, 2007).
Glenn, “Paper on versatility of adult stem cells comes under question” The Chronicle; (Feb. 26, 2007).
Holden, “Stem Cells. Controversial marrow cells coming into their own?” Science; 315:760-761 (2007).
Jiang et al., “Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain” Exp. Hematol.; 30:896-904 (2002).
Jiang et al., “Pluripotency of mesenchymal stem cells derived from adult marrow” Nature; 418:41-49 (2002).
Lerner et al., “Stem cell study was flawed, U panel finds” Star Tribune; (Feb. 27, 2007).
Noonan, “Limitations on the usefulness of adult stem cells” Patent Docs (Feb. 28, 2007).
Pincock, “Adult stem cell report questioned” The Scientist (Feb. 26, 2007).
Reyes et al., “Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells” Blood; 98:2615-25 (2001).
Serafini et al., “Hematopoietic reconstitution by multipotent adult progenitor cells: precursors to long-term hematopoietic stem cell” J. Exp. Med.; 204:129-139 (2007).
Anjos-Afonso and Bonnet, “Nonhematopoietic/endothelial SSE-1+ cells define the most primitive progenitors in the adult murine bone marrow mesenchymal compartment” Blood; 109:1298-1306 (2007).
Bertani et al., “Neurogenic potential of human mesenchymal stem cells revisited: analysis by immunostaining, time-lapse video and microarray” J Cell Sci.; 118:3925-36 (2005).
Bjornson et al., “Turning brain into blood: a hematopoietic fate adopted by adult neural stem cells in vivo” Science; 283:534-537 (1999).
Horwitz et al., “Clarification of the nomenclature for MSC: the international society for cellular therapy position paper” Cytotherapy; 7:393-395 (2005).
Lu et al., “Induction of bone marrow stromal cells to neurons: differentiation, transdifferentiation, or artifact” J Neurosci Res; 77:174-91 (2004).
Neuhuber et al., “Reevaluation of in vitro differentiation protocols for bone marrow stromal cells: disruption of actin cytoskeleton induces rapid morophological changes and mimics neuronal phenotype” J Neurosci Res; 77:192-204 (2004).
Simonsen et al., “Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells” Nature Biotechnology; 20:592-596 (2002).
Zimmerman et al., “Lack of telomerase activity in human mesenchymal stem cells” Leukemia; 17:1146-1149 (2003).
Verfaillie, “Letter to the Editor” Experimental Hematology; (2007).
Jiang et al., “Pluripotency of mesenchymal stem cells derived from adult marrow, Supplemental Information for Verfaillie Corrigendum” Nature; 418:41-49 (2002).
Applicants' Communication submitted to the USPTO in U.S. Appl. No. 11/238,234 on Oct. 2, 2007 and the accompanying Forms 1449.
Applicants' Supplemental Information Disclosure Statement submitted to the USPTO in U.S. Appl. No. 11/238,234 on Oct. 4, 2007 and the accompanying Form 1449.
Applicants' Second Communication submitted to the USPTO in U.S. Appl. No. 11/238,234 on Dec. 24, 2008 and the accompanying Form PTO/SB/08b.
Giles, J., “The trouble with replication” Nature, 422:344-347 (2006).
Verfaillie, C.M., “Multipotent adult progenitor cells: an update” Novartis Found. Symp., 254:55-65 (2005).
Public Statement from the University of Minnesota, 2008.
Blazer Bruce
Tolar Jakub
Verfaillie Catherine M.
Lankford Leon B
Regents of the University of Minnesota
Tarolli, Sundheim Covell & Tummino LLP
LandOfFree
MAPC administration for the treatment of lysosomal storage... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with MAPC administration for the treatment of lysosomal storage..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and MAPC administration for the treatment of lysosomal storage... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2721958